ACELYRIN, INC. (SLRN) has issued an update.
ACELYRIN, INC. has released promising data from its clinical trials on Izokibep, showing positive results for Psoriatic Arthritis and prolonged benefits in Hidradenitis Suppurativa, enhancing patient quality of life. The company has also resolved a previous dose-sequencing error through audits and plans to use the corrected Psoriatic Arthritis study as one of two pivotal trials. As ACELYRIN continues its clinical development program, it will transition the majority of its service needs by the end of the first quarter of 2024 after parting ways with the vendor Fortrea.
See more data about SLRN stock on TipRanks’ Stock Analysis page.
